Life Sciences Partners’ Curetis sets IPO price range

Katharina Semke
28 October 2015

Tweet
Facebook
LinkedIn
Google plus
Send to

Curetis, a medical diagnostics company backed by Life Sciences Partners, has set a price range of €9.5-12.0 per share for its upcoming IPO.

The company expects to list on the Euronext in Amsterdam and Euronext Brussels on 26 November. The offering seeks to raise €29.3m of gross proceeds, with a possible maximum of €50m.

Curetis will float approximately 15% of the total number of shares in the company, if the overallotment option is exercised.

Besides Life Sciences Partners, Curetis is also owned by Aeris Capital, Forbion, HBM Partners, BioMed Partners, Roche Venture Fund, Qiagen, CD-Venture and KfW. Management and shareholders agreed on a lock-up period of 12 months.

RBC Capital Markets is acting as sole global coordinator for the IPO. RBC and Bank Degroof Petercam are together the joint bookrunners. ICF Bank is lead manager for the offering.

Proceeds from the flotation will be used to build a commercial marketing, sales and support presence in the US. The company also hopes to expand research and development efforts in both the US and Europe.